Q1 2025 Aarti Drugs Ltd Earnings Call Transcript
Key Points
- Formulation segment's revenues grew by 4.2% quarter on quarter, reaching INR70.4 crores.
- The greenfield project at Gujarat Sayakha for specialty chemicals and intermediates is on track and expected to commence by the end of Q2 FY25.
- The company incurred CapEx of INR52 crores in Q1 FY25, mainly towards capacity expansion, backward integration, and new product launches.
- The company anticipates a total CapEx of INR200 crores for the full year, mainly funded through internal accruals and partly through term loans.
- Aarti Drugs Ltd (BOM:524348) plans to expand its capabilities and enhance offerings in the oncology therapeutic area.
- There was a drop in revenues to INR557 crores due to lower realization from negative rate variance and subdued export market demand in the API business.
- EBITDA margins stood at 11.9%, which is lower than pre-COVID levels of 15-16%.
- The company faced teething issues for the scale-up of the dermatologic products facility in Tarapur, leading to a negative impact of around INR6 crores at PBT level.
- A fire incident at the N-198 unit in Tarapur disrupted production operations temporarily.
- Export volumes were impacted by almost 8% year on year, contributing to lower overall EBITDA margins.
Ladies and gentlemen, good day, and welcome to Aarti Drugs Limited Q1 FY25 earnings conference call. This conference call may contain forward-looking statements about the company which are based on beliefs, opinions, and expectations of the company as on the date of this call. These statements are not the guarantees of future performance and involve risk and uncertainties that are difficult to predict.
As a reminder, all the participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Adhish Patil, [Promoter and CEO] of Aarti Drugs Limited. Thank you and over to you.
Good morning, everyone, and a very warm welcome on the behalf of Aarti Drugs management for the earnings conference call of Aarti Drugs for the June quarter 2024. On this call, we are joined by Mr. Harshit
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
